VCs Put $15M Into New Start-Up From Proteolix Founder
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech, Arvinas, will pursue therapies that degrade proteins, a process that could lead to therapeutic approaches to targets previously thought to be undruggable. The $15 million in venture funding is augmented by $3.5 million from the state of Connecticut.